Scarica l'app Stockscreener
85.74
0.28%
-0.24
Dopo l'orario di chiusura:
85.74
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$85.98
Aprire:
$86.11
Volume 24 ore:
2.39M
Relative Volume:
0.71
Capitalizzazione di mercato:
$32.35B
Reddito:
$4.82B
Utile/perdita netta:
$930.40M
Rapporto P/E:
36.67
EPS:
2.3381
Flusso di cassa netto:
$1.43B
1 W Prestazione:
+0.80%
1M Prestazione:
-4.04%
6M Prestazione:
+32.68%
1 anno Prestazione:
+25.30%
Intervallo 1D:
$85.14
$87.08
Intervallo di 1 settimana:
$83.30
$88.87
Portata 52W:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
85.74 | 32.35B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
102.45 | 177.28B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.63 | 121.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
304.40 | 116.76B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.58 | 66.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.29 | 50.89B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-07 | Iniziato | Barclays | Overweight |
| 2026-06-23 | Iniziato | Deutsche Bank | Buy |
| 2026-05-12 | Iniziato | The Benchmark Company | Buy |
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research
Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions
DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alpha
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom faces a class action over an alleged data breach that ShinyHunters claimed responsibility for. - Claim Depot
Vaso Stock Surges 149% in a Year: What's Behind the Rally? - TradingView
Vaso Stock Surges 149% in a Year: What's Behind the Rally? - Zacks Investment Research
A Look at DexCom Inc (DXCM) After 5.1% Gain -- GF Value $103.59 vs Price $87.71 - GuruFocus
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom gains as NEJM publication boosts Medicare coverage hopes - TradingView
Landmark Dexcom CONNECT Study Published in The New England Journ - GuruFocus
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin - Dexcom
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Yahoo Finance
DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation - ChartMill
Here's What to Expect From DexCom’s Next Earnings Report - inkl
Here's What to Expect From DexCom’s Next Earnings Report - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
BTIG Adjusts Price Target on DexCom to $96 From $90 - marketscreener.com
DexCom, Inc. (0A4M.L) stock price, news, quote and history - Yahoo Finance UK
DexCom, Inc. (DXCM) options chain – Yahoo Finance - Yahoo Finance Singapore
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Evercore ISI Adjusts Price Target on DexCom to $110 From $90 - marketscreener.com
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time - www.marketscreener.com
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time - Yahoo Finance
DexCom Inc (DXCM) Stock Down 4.0% -- Now Undervalued? GF Score: 95/100 - GuruFocus
DexCom Falls as Investors Appear to Take Profits Ahead of Earnings - Quiver Quantitative
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading - Business Wire
Dexcom Launches Largest Dexcom U Program Season Yet, Supporting College Athletes with Diabetes (DXCM) - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
DexCom stock gains 1.22 percent ahead of October earnings - AD HOC NEWS
Continuous Glucose Monitoring Market Size, Share [2026-2034] - Fortune Business Insights
Dexcom Hit With New Lawsuits Over G7 Monitor Failures - Medical Device and Diagnostic industry
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - Zacks Investment Research
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - TradingView
DexCom (NASDAQ:DXCM): Strong Growth Paired With a High-Quality Technical Setup - ChartMill
DXCM Maintains by RBC Capital -- Price Target Raised to $105 - GuruFocus
ShinyHunters new leak site lists O’Reilly and Dexcom breaches - cybernews.com
DEXCOM INC : RBC RAISES TARGET PRICE TO $105 FROM $90 - Moomoo
ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia - GlobeNewswire Inc.
RBC Raises Price Target on DexCom to $105 From $90, Keeps Outperform Rating - marketscreener.com
Under a preset trading plan, DexCom (DXCM) EVP Sadie Stern sells 2,565 shares. - Stock Titan
Here's Why DexCom (DXCM) is a Strong Growth Stock - Zacks Investment Research
Why DexCom Could Be the Big Winner Out of Oura’s IPO - Barron's
Dexcom Data Points to a CGM Awareness Gap, and Room to Grow - Medical Product Outsourcing
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dexcom Inc Azioni (DXCM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MICHAEL BROWN | Officer |
Oct 15 '26 |
Proposed Sale |
85.48 |
1,700 |
145,316 |
0 |
| Stern Sadie | EVP Chief People & Culture Off |
Sep 28 '26 |
Sale |
86.15 |
2,565 |
220,975 |
123,478 |
| SADIE STERN | Officer |
Sep 28 '26 |
Proposed Sale |
86.15 |
2,565 |
220,975 |
0 |
| Brown Michael Jon | EVP Chief Legal Compliance Off |
Sep 15 '26 |
Sale |
84.04 |
1,700 |
142,868 |
99,885 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Sale |
84.04 |
6,539 |
549,538 |
29,293 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Proposed Sale |
84.04 |
6,539 |
549,538 |
0 |
| MICHAEL BROWN | Officer |
Sep 15 '26 |
Proposed Sale |
84.04 |
1,700 |
142,868 |
0 |
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Sale |
84.02 |
1,550 |
130,231 |
35,832 |
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Proposed Sale |
84.02 |
1,550 |
130,231 |
0 |
| Sylvain Jereme M | EVP, Chief Financal Officer |
Sep 10 '26 |
Sale |
83.27 |
3,638 |
302,936 |
146,828 |
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):